ISA to Present Results of Randomized Phase II Study of ISA101b in Head and Neck Cancer at the ASCO Annual Meeting 2024

ISA Pharmaceuticals to present at the ASCO Annual Meeting 2024

ISA reports highlights of randomized Phase 2 cancer vaccine trial in head & neck cancer

ISA to Present at the 4th Annual Virtual H.C. Wainwright HBV Conference on October 25th

First Patient with Chronic Hepatitis B Dosed with ISA104 in First-in-Human Phase 1 Study

The combination of ISA101b and Libtayo® shows promising results in patients whose head and neck cancer progressed on anti-PD1 therapy

ISA Pharmaceuticals to Attend and Present at Upcoming Scientific and Business Conferences

ISA Pharmaceuticals and Cancer Focus Fund Announce $5 Million Investment to Support First-in-Human Trial of ISA’s Novel Immunotherapy ISA103 in Uveal Melanoma

ISA Completes Enrolment in Randomized Double Blind Phase 2 Clinical Trial of ISA101b in HPV16 induced Oropharyngeal Cancer

Professor Melief to receive 2022 SITC Pedro J. Romero Award